Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AYTU Aytu BioPharma	$2.20 +0.9%	$2.29	$0.95 ▼ $2.85	$19.75M	0.13	113,806 shs	93,694 shs
CING Cingulate	$4.19 +5.0%	$4.55	$3.02 ▼ $11.88	$22.68M	-0.74	159,309 shs	131,694 shs
FNCH Finch Therapeutics Group	$13.48	$12.77	$10.15 ▼ $15.85	$21.65M	1.19	2,237 shs	66 shs
HCWB HCW Biologics	$3.45 +4.2%	$4.33	$2.77 ▼ $100.80	$7.43M	0.66	31,502 shs	16,833 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AYTU Aytu BioPharma	0.00%	-0.45%	-16.98%	+12.24%	-18.22%
CING Cingulate	0.00%	+3.71%	-21.97%	+14.48%	-61.91%
FNCH Finch Therapeutics Group	0.00%	+6.14%	+7.84%	+3.69%	+22.10%
HCWB HCW Biologics	0.00%	-15.65%	-19.01%	-58.78%	-79.90%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AYTU Aytu BioPharma	3.149 of 5 stars	3.5	2.0	0.0	3.4	0.0	0.0	0.6
CING Cingulate	2.6588 of 5 stars	3.5	3.0	0.0	0.0	2.8	0.8	0.6
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
HCWB HCW Biologics	2.1482 of 5 stars	3.5	3.0	0.0	0.0	1.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AYTU Aytu BioPharma	3.00	Buy	$10.00	354.55% Upside
CING Cingulate	3.00	Buy	$26.25	526.49% Upside
FNCH Finch Therapeutics Group	0.00	N/A	N/A	N/A
HCWB HCW Biologics	3.00	Buy	$35.00	914.49% Upside

Current Analyst Ratings Breakdown

Latest HCWB, FNCH, CING, and AYTU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/22/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$61.00 ➝ $62.00
8/8/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/1/2025	AYTU Aytu BioPharma	Lake Street Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$8.00
6/30/2025	AYTU Aytu BioPharma	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
5/29/2025	HCWB HCW Biologics	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$120.00 ➝ $35.00
5/27/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AYTU Aytu BioPharma	$81M	0.24	N/A	N/A	$4.64 per share	0.47
CING Cingulate	N/A	N/A	N/A	N/A	$1.02 per share	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	$14.25 per share	N/A
HCWB HCW Biologics	$2.57M	2.89	N/A	N/A	($0.02) per share	-172.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AYTU Aytu BioPharma	-$15.84M	-$0.72	N/A	∞	N/A	2.37%	3.51%	0.91%	9/25/2025 (Estimated)
CING Cingulate	-$15.55M	-$4.10	N/A	N/A	N/A	N/A	-232.16%	-132.07%	11/6/2025 (Estimated)
FNCH Finch Therapeutics Group	-$74.75M	-$8.82	N/A	∞	N/A	N/A	-69.14%	-26.92%	N/A
HCWB HCW Biologics	-$30.02M	-$14.04	N/A	∞	N/A	-1,368.55%	N/A	-40.72%	N/A

Latest HCWB, FNCH, CING, and AYTU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/19/2025	Q2 2025	CING Cingulate	-$0.82	-$1.09	-$0.27	-$1.09	N/A	N/A
8/18/2025	Q2 2025	HCWB HCW Biologics	$1.80	-$6.79	-$8.59	-$6.79	$7.00 million	$0.01 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AYTU Aytu BioPharma	N/A	N/A	N/A	N/A	N/A
CING Cingulate	N/A	N/A	N/A	N/A	N/A
FNCH Finch Therapeutics Group	N/A	N/A	N/A	N/A	N/A
HCWB HCW Biologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AYTU Aytu BioPharma	0.27	1.03	0.87
CING Cingulate	N/A	1.52	1.87
FNCH Finch Therapeutics Group	N/A	3.87	3.87
HCWB HCW Biologics	N/A	0.11	0.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AYTU Aytu BioPharma	33.49%
CING Cingulate	41.31%
FNCH Finch Therapeutics Group	21.77%
HCWB HCW Biologics	2.96%

Insider Ownership

Company	Insider Ownership
AYTU Aytu BioPharma	3.60%
CING Cingulate	5.27%
FNCH Finch Therapeutics Group	44.90%
HCWB HCW Biologics	42.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AYTU Aytu BioPharma	160	8.98 million	8.65 million	Not Optionable
CING Cingulate	20	5.41 million	5.13 million	Not Optionable
FNCH Finch Therapeutics Group	190	1.61 million	885,000	No Data
HCWB HCW Biologics	40	2.15 million	1.23 million	Not Optionable

HCWB, FNCH, CING, and AYTU Headlines

Recent News About These Companies

HCW Biologics Inc.: HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

August 19, 2025 | finanznachrichten.de

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

August 19, 2025 | manilatimes.netM

HCW Biologics Inc. Reports Q2 2025 Financial Results and Business Developments

August 18, 2025 | quiverquant.comQ

HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results

August 18, 2025 | globenewswire.com

HCW Biologics Second Quarter 2025 Earnings: US$0.90 loss per share (vs US$16.16 loss in 2Q 2024)

August 16, 2025 | finance.yahoo.com

HCW Biologics Amends Equity Purchase Agreement

August 16, 2025 | msn.com

HCW Biologics Delays Q2 10-Q Filing

August 15, 2025 | tipranks.com

Hcw Biologics Revenue Plunges 98 Percent

August 14, 2025 | aol.comA

HCW Biologics Inc News (HCWB) - Investing.com

July 2, 2025 | investing.com

Insiders Re-Evaluate Their US$3.05m Stock Purchase As HCW Biologics Falls To US$6.9m

July 2, 2025 | uk.finance.yahoo.com

HCW Biologics Completes Warrant Exercise with Armistice

July 1, 2025 | tipranks.com

HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors

June 27, 2025 | globenewswire.com

HCW Biologics Inc.: HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

June 26, 2025 | finanznachrichten.de

HCW Biologics Inc. Regains Compliance with Nasdaq Listing Requirements

June 26, 2025 | quiverquant.comQ

HCW Biologics Regains Nasdaq Compliance as of June 2025

June 26, 2025 | tipranks.com

HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements

June 26, 2025 | globenewswire.com

HCW Biologics and WY Biotech Finalize Licensing Agreement for HCW11-006, Marking Strategic Development Partnership

June 6, 2025 | nasdaq.com

HCW Biologics Meets Nasdaq Listing Requirements in May 2025

June 5, 2025 | tipranks.com

HCW Biologics Sinks on Alliance with WY Biotech

June 4, 2025 | baystreet.ca

HCW Biologics Secures Licensing Agreement with WY Biotech

June 4, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

HCWB, FNCH, CING, and AYTU Company Descriptions

Aytu BioPharma NASDAQ:AYTU

$2.20 +0.02 (+0.92%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$2.19 -0.01 (-0.45%)

As of 08/22/2025 07:46 PM Eastern

Aytu Biopharma, Inc. is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers. Its products include Adzenys ER, Adzenys XR-ODT, Cotempla XR-ODT, Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor, Generic Tussionex, Tuzistra XR, and ZolpiMist. The company was founded on August 9, 2002 and is headquartered in Englewood, CO.

Cingulate NASDAQ:CING

$4.19 +0.20 (+5.01%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$4.03 -0.16 (-3.82%)

As of 08/22/2025 07:28 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Finch Therapeutics Group NASDAQ:FNCH

$13.48 0.00 (0.00%)

As of 08/22/2025

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.

HCW Biologics NASDAQ:HCWB

$3.45 +0.14 (+4.23%)

Closing price 08/22/2025 03:59 PM Eastern

Extended Trading

$3.46 +0.01 (+0.43%)

As of 08/22/2025 06:13 PM Eastern

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time